RespiCare^®

Therapeutic Segment:
Anti-asthmatic

Generic Name:
Montelukast Sodium

Description:
RespiCare® (Montelukast Sodium) is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor, stimulation of which by circulating leukotrienes is thought to play a role in the pathogenesis of asthma. It suppresses both early and late bronchoconstrictor responses to inhaled antigens or irritants, but is not suitable for the management of acute attack of asthma. Montelukast Sodium is described chemically as [R-(E)-1-[[[1-[3[2- (7-chloro-2-quinolinyl) ethenyl] phenyl] -3-[2(1-hydroxy- 1methyelhyl) phenyl] propyl]thio]methyl] cyclopropaneacetic acid, monosodium salt.

Indication:
RespiCare® (Montelukast sodium) is indicated for the prophylaxis and chronic treatment of asthma including:

• The prevention of day and night time symptoms.
• The treatment of aspirin-sensitive asthmatic patients.
• The prevention of exercised-induced bronchoconstriction.

RespiCare® (Montelukast sodium) is also indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

Formulation:

• Chewable Tablets
• Tablets
• Sachet

Strength:

• Chewable Tablets : 4mg, 5mg
• Tablets : 10mg
• Sachet : 4mg

Pack Size:

• Chewable Tablets : 14’s
• Tablets : 14’s
• Sachet : 14’s